InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,707.14
(
-0.20%
)
US TECH 100
19,242.00
(
-0.41%
)
Dow Jones
42,127.59
(
0.01%
)
Brent Oil
74.53
(
1.08%
)
Bitcoin
63,224.30
(
-0.16%
)

Replies to post #302 on Clovis Oncology Inc (fka CLVSQ) (CLVSQ)

Replies to #302 on Clovis Oncology Inc (fka CLVSQ) (CLVSQ)
icon url

MaryMary158

12/05/19 10:39 AM

#303 RE: sorkin #302

Possibly next week.
icon url

MaryMary158

12/05/19 10:52 AM

#304 RE: sorkin #302

So will you address my question please? Here is more on yours.

Obviously we already have Rubraca which is growing internationally. Then we have the prostrate updated filing due before year-end. And...

Rubraca and sacituzumab combo inmTNBC, advanced urothelial cancer (UC) and second-line metastatic NSCLC. Preliminary readout of Clovis and IMMU collaboration may be presented at SABCS in few days.